GlioCure transforms into a Limited Liability Company and closes a new round of financing
GlioCure, a preclinical-drug-development company specialized in neuro-oncology, announced today that during a recent combined general meeting, its shareholders ratified transformation... View Article
Valneva Initiates Phase 3 Clinical Trial for its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
Valneva, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet... View Article
Valneva Switches Focus to Bilateral Discussions to Supply its Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article
INRAE involved in a research project on non-hormonal female contraception
Accelerating Discovery for Non-Hormonal Contraceptives is one of the Grand Challenge programmes launched by the Bill & Melinda Gates Foundation... View Article
New member | Wetan
Wetan supports startups leaders or project leaders who need to finance their project successfully. The compant helps them build a... View Article
New member | LaFleur by DelleD
While the experimentation of the medical use of cannabis framed by the National Agency for Medicines began in France on... View Article
Update on XENOTHERA’s news
In March, XENOTHERA went on digging its wake to analyze the clinical efficacy of XAV-19. Marchwas the month for the... View Article
New member | Bioprox Healthcare
BIOPROX HEALTHCARE produces probiotics of bacterial origin belonging to about thirty different species mainly Lactobacillus (former genus name) and Bifidobacterium isolated from human... View Article
New member | Genourob
Genourob design, produce and commercialize medical devices for helping ACL tears diagnosis and for rehabilitation and fitness. Genourob has become the world... View Article
Valneva reports positive phase 1/2 data for its inactivated, adjuvanted COVID-19 vaccine candidate
VLA2001 was well tolerated with no safety concerns identified In the high dose group : IgG seroconversion rate of 100%... View Article